



Abattis Announces Increase in Private Placement

Vancouver, BC – February 10, 2012 – Abattis Biologix Corporation (CNSX:FLU) (“Abattis” or the “Company”) announces that it has amended the terms of its private placement previously announced on December 11, 2011, to increase the offering to up to 6,000,000 units (“Units”) for proceeds of up to \$300,000.

Each Unit is comprised of one share and one warrant, with each warrant exercisable into a share for a period of 12 months at an exercise price of \$0.07/share. The second tranche of this private placement is expected to close on or around February 14, 2012.

The Company may pay a finder’s fee on this financing.

Proceeds received from the sale of the Units will be used for general working capital.

About Abattis Biologix Corporation

Abattis Biologix is a specialty biotechnology company engaged in the development, licensing, sale and distribution of botanical-based antiviral/bacteria, anti-tumor and pain relief products. At present, the Company is focused on refining and bringing to market a portfolio of proprietary nutraceutical formulations of botanical agents with demonstrated ability to inhibit the growth of, and reduce the severity and duration of various strains of human influenza and other viral diseases. Continuing research is being conducted by the Company.

ON BEHALF OF THE BOARD OF DIRECTORS

“Mike Withrow”

Mike Withrow
President & CEO
For information please contact the Company
Tel: 604-778-908-6650

Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.

Abattis Biologix Corporation, 310 - 885 Dunsmuir Street. Vancouver, BC. V6C 1N5